One of the most common questions in peptide research is whether you need to cycle compounds. The answer depends entirely on which peptide you're running and the mechanism involved. There's no one-size-fits-all answer.
Peptides where cycling is generally recommended:
GH Secretagogues (ipamorelin, GHRP-2, GHRP-6, Mod GRF): The concern is pituitary desensitization — if you continuously stimulate GH release, the pituitary may downregulate its response over time. Common cycling approaches: 5 days on / 2 days off, or 3 months on / 1 month off. Some researchers report no decline in efficacy without cycling, but the precautionary approach is reasonable given the mechanism.
Melanotan II: After achieving desired pigmentation, most researchers drop to maintenance dosing rather than continuous loading. The melanocytes don't need constant stimulation once melanin production has been upregulated. Continuous high-dose MT-II increases the risk of side effects (new moles, excessive darkening) without proportional benefit.
Peptides where cycling is less clear:
BPC-157: No strong evidence that BPC-157 loses effectiveness with continuous use. Most researchers run it for a defined protocol (8-12 weeks for a specific injury) and stop when the research goal is achieved rather than cycling on/off indefinitely.
TB-500: Similar to BPC-157 — most protocols are goal-oriented rather than cycled. Run it until the target tissue has responded, then discontinue.
Peptides where cycling is generally NOT recommended:
GLP-1 agonists (semaglutide, tirzepatide): These work best with continuous use. Discontinuing GLP-1 peptides typically results in rapid return of appetite and weight regain. The clinical research is clear that maintained administration produces maintained results. Cycling on/off undermines the entire research approach.
Selank/Semax: These nootropic peptides can be used continuously or intermittently based on cognitive demands. No documented desensitization. Some researchers use them daily during high-demand periods and take breaks otherwise.
General principles:
If a peptide works by stimulating a receptor, desensitization is theoretically possible with continuous use — consider cycling. If a peptide works by providing raw material or modulating an enzyme/pathway, desensitization is less likely. If you notice declining effectiveness at a stable dose over weeks, that's a signal to take a break regardless of the compound. When in doubt, 5-on/2-off is a conservative approach that most researchers consider safe.
